

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/70, C07K 7/00, 14/00, 14/16	A1	(11) International Publication Number: WO 99/06599 (43) International Publication Date: 11 February 1999 (11.02.99)
(21) International Application Number: PCT/US98/16160 (22) International Filing Date: 31 July 1998 (31.07.98) (30) Priority Data: 08/904,826 1 August 1997 (01.08.97) US (71) Applicant (for all designated States except US): GENETIC SYSTEMS CORPORATION [US/US]; 6565-185th Avenue N.E., Redmond, WA 98052 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COLEMAN, Patrick, F. [US/US]; 17211-77th Avenue West, Edmonds, WA 98026 (US). CHONG-DUG SU, Peter [US/US]; 6001-84th Avenue S.E., Mercer Island, WA 98040 (US). MONJI, Nobuo [US/US]; 3545 N.E. 98th Street, Seattle, WA 98115 (US). COLE, Carol-Ann [US/US]; 1116-18th Avenue East, Seattle, WA 98112 (US). GOSHORN, Alice, Kamp [US/US]; 20309-17th Avenue N.W., Seattle, WA 98177 (US). (74) Agents: ENEBO, Daniel, J. et al.; Fredrikson & Byron, P.A., 1100 International Centre, 900 Second Avenue South, Minneapolis, MN 55402-3397 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SYNTHETIC ANTIGEN FOR THE DETECTION OF ANTIBODIES IMMUNOREACTIVE WITH HIV VIRUS (57) Abstract <p>Novel polypeptides, and recombinant polynucleotide sequences encoding the same, are provided. The polypeptides have substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SYNTHETIC ANTIGEN FOR THE DETECTION OF
ANTIBODIES IMMUNOREACTIVE WITH HIV VIRUS

Field of the Invention

This invention relates to synthetic polypeptides, recombinant polypeptides and
5 recombinant polynucleotide sequences encoding the same, useful for detecting antibodies
associated with human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) (as
used herein, "HIV" used without reference to the type shall mean either or both types), and
particularly relates to synthetic polypeptides which mimic antigenic epitopes of the gene
products of the HIV polymerase region.

10 Background of the Invention

This application is a continuation in part of U.S. application Ser. No. 08/904,826
filed August 1, 1997, the disclosure of which is incorporated herein by reference.

Human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) are known to
cause acquired immune deficiency syndrome (AIDS). Both viruses apparently exhibit
15 similar modes of transmission. HIV-1 and HIV-2 were both isolated in the early 1980's
from African AIDS patients. Since then, cases have been found in most countries of the
world. Because the HIV viruses exhibit rapid genetic drift, widely divergent strains are
emerging. Thus, detection and treatment of variant strains has proven to be challenging
and difficult.

20 Individuals with antibodies reactive with HIV-1 and/or HIV-2 are determined by
immunoassays of the conventional sandwich ELISA format. These assays are comprised
of an immobilized viral antigen, that may be comprised of viral lysate, retrovirus proteins
or natural or synthetic polypeptides, that is contacted with blood or serum components

suspected of containing HIV antibodies. While the existing commercial tests appear to have significantly diminished the transmission of HIV virus in blood products, each test configuration may have some disadvantages.

The possible disadvantages of viral lysate tests include: the need to grow and
5 handle large quantities of live infectious virus; the possibility that the live virus might be incorporated into test materials; the variable nature of the resulting viral lysate; and the substantial number of false positive and false negative results that require additional confirmatory testing. These disadvantages may also be associated with the use of isolated viral proteins as antigens.

10 The use of synthetic polypeptides, (as used herein, "synthetic polypeptide" and "polypeptide" shall mean any one, all or a combination of the following: synthetic polypeptide, recombinant polypeptide, or polypeptide) which can be engineered to immunologically mimic antigenic epitopes of the HIV viruses, may avoid some of the above-mentioned disadvantages. One area of concern with the use of synthetic
15 polypeptides (less than or equal to 60 residues in length) in diagnostic assays is the consideration that viral antigenic drift could result in the failure to detect HIV-1 or HIV-2 infected sera using these assays, presumably due to the limited presentation of viral epitopes. One method of guarding against such an occurrence is to include polypeptides from different immunodominant regions of the viral genome. Thus, synthetic
20 polypeptides that immunologically mimic immunodominant regions of the HIV-1 and HIV-2 pol gene products are important additions to the already described polypeptides that mimic the env, gag, and pol proteins of HIV-1 and HIV-2. U.S. Patent Nos. 4,629,783 and 5,075,211 describe synthetic polypeptides that mimic antigenic determinants of HIV-1.

Cosand U.S. Patent 5,075,211 describes synthetic polypeptides that immunologically mimic antigenic epitopes of HIV-1 proteins from the pol region, including two polypeptides which are similar to the polypeptides of this invention. In blood screening assays, the greater the immunoreactivity of the antigens used in the assay method, the less likely antibodies to a new variant or subtype of HIV-1 or HIV-2, present in a patient's sample, will be left undetected.

U.S. Patent 5,306,466 describes an "HIV-3 retrovirus" which was initially believed to be separate and distinct from HIV-1 and HIV-2. Researchers have since determined that the HIV-3 retrovirus is merely a particular subtype of HIV-1, now referred to as subtype O, or Group O (R. De Leys, et. al., J.Virol.: 1207-1216 (1990); L.G Gürtler, et. al., J.Virol.:1581-1585 (1994)).

By comparing various HIV-1 isolates researchers have shown that some regions of the genome are highly variable while others are reasonably well conserved. Similar polymorphisms have also been observed for HIV-2.

Despite the apparent similarities in disease state and transmission of HIV-1 and HIV-2 viruses, the virus types have been differentiated based on their genetic divergence. Based on genetic analysis viral isolates can be grouped according to their genetic homology to previous isolates. Today, HIV-1 and HIV-2 form the two main branches of the HIV genetic tree. DNA hybridization studies suggest that, while regions of extensive homology exist between HIV-1 and HIV-2, other regions seem very divergent. (Clavel et al, Science 233: 343 (1986)). In fact, HIV-2 has been shown to have, overall, only about 40% homology with HIV-1, and studies have shown little immunological cross reactivity between the envelope glycoproteins. The limited serologic cross reactivity between these

viruses makes screening assays based on HIV-1 antigens insufficient for screening or diagnosis of HIV-2 infection in human sera.

SUMMARY OF THE INVENTION

Polypeptide sequences capable of mimicking immunodominant regions of HIV-1
5 or HIV-2 proteins, encoded in the polymerase region, have been identified. These
synthetic polypeptides, recombinant polypeptides and recombinant polynucleotide
sequences encoding the same, are useful in the preparation of reagents for the screening of
blood and blood products for exposure to HIV viruses. The polypeptides can be used in
various specific binding assays for the detection of antibodies to HIV-1 and/or HIV-2
10 virus, for the detection of HIV-1 and/or HIV-2 antigens, or as immunogens in vaccine
compositions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a plasmid map of one of the recombinant constructs of the present
invention, more specifically that of pGEX/*pol23*.

15 FIG. 2 depicts a plasmid map of one of the recombinant constructs of the present
invention, more specifically that of pGEX/*pol7*.

FIG. 3 depicts a plasmid map of one of the recombinant constructs of the present
invention, more specifically that of pQE/*pol23*.

FIG. 4 depicts a plasmid map of one of the recombinant constructs of the present
20 invention, more specifically that of pQE/*pol7*.

FIG. 5 depicts a plasmid map of one of the recombinant constructs of the present
invention, more specifically that of pThioHis/*pol23*.

FIG. 6 depicts a plasmid map of one of the recombinant constructs of the present invention, more specifically that of pThioHis/pol7.

DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Novel polypeptides are provided that immunologically mimic proteins encoded by the HIV-1 or HIV-2 retroviruses, respectively, particularly proteins encoded in the polymerase region of the viral genome. Each polypeptide of the invention may be modified by introducing conservative or non-conservative substitutions into the polypeptide, usually fewer than 20 number percent, and more usually fewer than 10 number percent of the amino acids being exchanged. In those situations where regions are found to be structurally polymorphic, it may be desirable to vary one or more particular amino acid to more effectively mimic the differing epitopes of the different retroviral strains. In many instances to provide chemical stability, methionine may be replaced by norleucine (Nor).

One particularly useful means of choosing appropriate amino acid substitutions in a polypeptide of the invention would be a substitution which occurs naturally in one or more isolates of the virus.

In general, the term "polypeptide" or "peptide" used herein shall mean a chain of amino acid molecules possessing biological activity. The terms do not relate to a product of any specific length.

It should be understood that the polypeptide employed in the subject invention need not be identical to any particular HIV-1 or HIV-2 polypeptide sequence, so long as the subject compound is able to immunologically mimic an epitope of the pol region of at least one of the strains of the HIV-1 or HIV-2 retrovirus. Therefore, the subject

polypeptide may be modified to include various changes, as mentioned above, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative substitutions it is intended substitutions within groups such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; phe, tyr; and nor, met. Usually, the sequence will not differ by more than 20% from the sequence of at least one strain of an HIV-1 or HIV-2 retrovirus except where additional amino acids may be added at either terminus for the purpose of providing an "arm" by which the polypeptide of this invention may be conveniently immobilized. The arms will usually be at least 1 amino acid and may be 50 or more amino acids, more often 1 to 10 amino acids, in length. A polypeptide in which the amino acid sequence is modified by the substitution, addition, or deletion of amino acid residues should retain substantially all of the immunological reactivity of the unmodified polypeptide, which may be conveniently measured by radioimmuno-precipitation, immunofluorescence, or enzyme-linked immunosorbant assays.

15 In addition, one or more amino acids may be added to the termini of an oligopeptide or polypeptide to provide for ease of linking polypeptides one to another, for coupling to a support or larger polypeptide, for modifying the physical or chemical properties of the polypeptide or oligopeptide, or the like.

Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, may be introduced at the C- or N-terminus of the polypeptide to provide for a useful functionality for linking. Cysteine is particularly preferred to facilitate covalent coupling to other polypeptides or, for example, to form dimers by oxidation. To form polymers, it is preferred to have at least two cysteine residues present in the molecules being linked,

preferably by utilizing cysteine residues added to the terminal portions of the polypeptides.

Combinations of cysteine with intervening amino acid spacers are also useful. For example, two cysteine residues can be separated by one or more amino acid residue.

Glycine residues are particularly useful and from one to three glycine residues may be employed between amino acids. Lysine residues have also been found to be useful as linkers and from one to three lysine residues may be used to couple the polypeptides to a solid phase alone or in combination with other amino acids.

In addition, the subject polypeptide sequences may differ from the natural sequence after being modified by terminal-NH₂ acylation, e.g. acetylation, or thioglycolic acid amidation, terminal-carboxy amidation, e.g. with ammonia or methylamine, to provide stability, increased hydrophobicity for linking or binding to a support or other molecule, or for polymerization.

The polypeptides of the invention, derived from the polymerase region of HIV-1 are described below. The family of HIV-1 polypeptides are encoded by the genomic polynucleotide sequences (LAI or BRU isolate) encompassing base pairs (bp) 4448 through (bp) 4585 (numbering of Genbank HIVBRUCG; Accession K02013, BRU isolate) or is encoded in the pol open reading frame from about amino acid residue numbers 940 to about 985.

Polypeptide I has the following polypeptide sequence:

20

(I) BRU124E

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-
Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-
Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide II, also designated BRU124EX, has the following polypeptide sequence:

(II) BRU124EX

10 W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-
Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-
Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide III, also designated BRU124F1X, has the following polypeptide sequence:

(III) BRU124F1X

20 W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-
Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Ser-Asp-
Ile-Lys-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide,

the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide IV, also designated

5 BRU124F3X, has the following polypeptide sequence:

(IV) BRU124F3X

10 W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-
Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-
Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or
15 one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

The polypeptides of the invention, derived from the polymerase region of HIV-2 are described below. Polypeptide V, also designated ROD124E1, is encoded by the polynucleotide sequence of the HIV-2 genome encompassing base pairs (bp) 4694 through (bp) 4861 (numbering by Genbank HIV2ROD; Accession M15390, HIV-2ROD isolate) or
20 is encoded in the pol open reading frame from about amino acid residue numbers 956 through 1001.

Polypeptide V has the following polypeptide sequence:

(V) ROD124E1

25 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-
Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-

Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-
Glu-Gly-Ala-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide VI , also designated ROD124EX, has the following polypeptide sequence:

(VI) ROD124EX

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-
Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-
Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-
Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide VII , also designated ROD124C2X, has the following polypeptide sequence:

(VII) ROD124C2X

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-
Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-
Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-
Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Thr-
Asp-Ile-Lys-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or
5 one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide VIII , also designated ROD124C1X, has the following polypeptide sequence:

(VIII) ROD124C1X

10 W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-
Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-
Val-Gly-Thr-Asp-Ile-Lys-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide,
15 the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide IX , also designated ROD123C3X, has the following polypeptide sequence:

20 (IX) ROD123C3X

X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-
Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-
Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-
Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

25 wherein X is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide,

the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide X, also designated POL2A1,
5 has the following polypeptide sequence:

(X) POL2A1

10 W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-
Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-
Val-Gly-Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-
Arg-Lys-Ala-Lys-Ile-Ile-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Another polypeptide of the invention, Polypeptide XI, also designated
ROD124C5X, has the following polypeptide sequence:

(XI) ROD124C5X

20 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-
Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-
Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-
Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a

carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂.

Of particular interest is the use of the mercaptan group of cysteines or thioglycolic acids used for acylating terminal amino groups or the like for linking two of the

5 polypeptides or oligopeptides or combinations thereof by a disulfide linkage or a longer linkage. To achieve this, compounds may be employed having bis-haloacetyl groups, nitroarylhalides, or the like where the reagents are specific for thio groups. Thus, the linking between the two mercapto groups of the different polypeptides or oligopeptides may be a single bond or a linking group of at least 2, usually at least 4, and not more than

10 about 16, usually not more than about 14 carbon atoms.

Alternatively, the region of the viral genome coding for the polypeptide of the invention may be cloned by conventional recombinant DNA techniques and expressed. These techniques include PCR mediated cloning, as well as, synthesis of single strand polynucleotide strands encoding the polypeptide of interest. See generally, Maniatis et al,

15 Molecular Cloning, A Laboratory Manual, CSH, Cold Spring Harbor Laboratory, 1982.

Fragments from a polynucleotide sequence may be employed for expression of polypeptide fragments, conservative base changes can be made, where the modified codon(s) code for the same amino acid(s), or non-conservative changes in the coding sequence may be made, where the resulting amino acid may be a conservative or non-

20 conservative change in the amino acid sequence, which was discussed previously.

The coding sequence may be extended at either the 5'- or 3'-terminus or both termini to extend the polypeptide, while retaining its epitopic site(s). The extension may

provide for an arm for linking, e.g., to a label, such as an enzyme, for joining this and other polypeptides together in the same chain, for providing antigenic activity, or the like.

For expression, the coding sequence will be provided with start and stop codons, promoter and terminator regions and usually a replication system to provide an expression
5 vector for expression in a cellular host, e.g., prokaryotic or eukaryotic, bacterial, yeast, mammal, etc.

The DNA sequence by itself, fragments thereof, or larger sequences, usually at least 15 bases, preferably at least 18 bases, may be used as probes for detection of retroviral RNA or proviral DNA. Numerous techniques are described, such as the
10 Grunstein-Hogness technique, Southern technique, Northern technique, dot-blot, improvements thereon, as well as other methodology. See, for example, WO 83/02277 and Berent et al, Biotechniques (1985) 3:208.

Conveniently, the polypeptide may be prepared as a fused protein, where the polypeptide may be the N- or C- terminus of the fused polypeptide. Commonly, the
15 polypeptide of interest is expressed as a "translational fusion," meaning that the expressed protein will have its amino terminus attached to a "partner" protein that is easily expressed in *E. coli*, or other well known expression systems. The fusion also may include a purification tag or "handle."

One example of such a fusion system is the use of a portion of the glutathione S-
20 transferase gene which encodes a protein that can be used in affinity-purification on glutathione-agarose resin. This fusion system is found in the commercially available pGEX plasmid (Pharmacia). A second example is the use of a portion of the dihydrofolate reductase gene as the fusion partner and a sequence encoding six histidine residues as the

handle. The "His-tag" allows the resulting fusion protein to be purified by Ni-NTA (nickel) chromatography. This fusion system is found in the commercially available pQE42 plasmid (QIAGEN). Similarly, a portion of the *E. coli* thioredoxin gene having a "His-patch" consisting of three histidine residues engineered into the thioredoxin coding
5 sequence allows purification of expressed proteins by Ni-NTA chromatography. This fusion system is found in the commercially available pThioHisA plasmid (Invitrogen).

A resulting fused protein could be used directly by itself as the reagent, or the subject polypeptide may be cleaved from all or a portion of the remaining sequence of the fused protein. With a polypeptide containing no internal methionines, by introducing a
10 methionine at the fusion site, the polypeptide may be cleaved employing cyanogen bromide. Where there is an internal methionine, it would be necessary to provide for a proteolytic cleavage site, e.g., polylysine and/or arginine or combinations thereof. Alternatively, the internal methionine could be substituted by an amino acid such as leucine and an N-terminal methionine added for cyanogen bromide cleavage. A wide
15 variety of proteases, including dipeptidases, are well known, and the appropriate processing signal could be introduced at the proper site. The processing signal may have tandem repeats so as to insure cleavage, since the presence of one or more extraneous amino acids will not interfere with the utility of the subject polypeptides.

Recombinant polynucleotide sequences of the invention encoding a number of
20 polypeptides, derived from the polymerase region of HIV-1 are described below. The sequences are derived from the HIV-1 genomic polynucleotide sequences (LAI isolate) encompassing base pairs (bp) 2549 through (bp) 3139, and base pairs 4391 (bp) through (bp) 4648, as found in the HIV-1 viral lysate.

Polynucleotide Sequence I, also known as *pol23*, has the following sequence:

(I) *pol23*

CCA GGG ATT AGA TAT CAG TAC AAT GTG CTT CCA CAG GGA TGG
 AAA GGA TCA CCA GCA ATA TTC CAA AGT AGC ATG ACA AAA ATC
 5 TTA GAG CCT TTT AGA AAA CAA AAT CCA GAC ATA GTT ATC TAT
 CAA TAC ATG GAT GAT TTG TAT GTA GGA TCT GAC TTA GAA ATA
 GGG CAG CAT AGA ACA AAA ATA GAG GAG CTG AGA CAA CAT CTG
 TTG AGG TGG GGA CTT ACC ACA CCA GAC AAA AAA CAT CAG AAA
 GAA CCT CCA TTC CTT TGG ATG GGT TAT GAA CTC CAT CCT GAT
 10 AAA TGG ACA GTA CAG CCT ATA GTG CTG CCA GAA AAA GAC AGC
 TGG ACT GTC AAT GAC ATA CAG AAG TTA GTG GGA AAA TTG AAT
 TGG GCA AGT CAG ATT TAC CCA GGG ATT AAA GTA AGG CAA TTA
 TGT AAA CTC CTT AGA GGA ACC AAA GCA CTA ACA GAA GTA ATA
 CCA CTA ACA GAA GAA GCA GAG CTA GAA CTG GCA GAA AAC AGA
 15 GAG ATT CTA AAA GAA CCA GTA CAT GGA GTG TAT TAT GAC CCA
 TCA AAA GAC TTA ATA GCA GAA ATA CAG AAG CAG GGG CAA GGC
 CAA

This sequence encodes the following amino acid sequence. (Without the intention
 20 of being bound by this teaching it is believed that the italicized amino acids represent
 particularly important residues to the immunoreactivity of the resulting polypeptide.)

(XII) *pol23*-aa Polypeptide Encoded by Polynucleotide Sequence (I) *pol23*

Pro-Gly-Ile-Arg-Tyr-Gln-Tyr-Asn-Val-Leu-Pro-Gln-Gly-Trp-Lys-Gly-Ser-Pro-Ala-Ile-
 Phe-Gln-Ser-Ser-Met-Thr-Lys-Ile-Leu-Glu-Pro-Phe-Arg-Lys-Gln-Asn-Pro-Asp-Ile-Val
 25 Ile-Tyr-Gln-Tyr-Met-*Asp-Asp*-Leu-Tyr-Val-Gly-Ser-Asp-Leu-Glu-Ile-Gly-Gln-His-Arg-
 Thr-Lys-Ile-Glu-Glu-Leu-Arg-Gln-His-Leu-Leu-Arg-Trp-Gly-Leu-Thr-Thr-Pro-Asp-Lys-
 Lys-His-Gln-Lys-Glu-Pro-Pro-Phe-Leu-Trp-Met-Gly-Tyr-Glu-Leu-His-Pro-Asp-Lys-Trp-
 Thr-Val-Gln-Pro-Ile-Val-Leu-Pro-Glu-Lys-Asp-Ser-Trp-Thr-Val-Asn-Asp-Ile-Gln-Lys-
 Leu-Val-Gly-Lys-Leu-Asn-Trp-Ala-Ser-Gln-Ile-Tyr-Pro-Gly-Ile-Lys-Val-Arg-Gln-Leu-
 30 Cys-Lys-Leu-Leu-Arg-Gly-Thr-Lys-Ala-Leu-Thr-Glu-Val-Ile-Pro-Leu-Thr-Glu-Glu-Ala-
 Glu-Leu-Glu-Leu-Ala-Glu-Asn-Arg-Glu-Ile-Leu-Lys-Glu-Pro-Val-His-Gly-Val-Tyr-Tyr-
 Asp-Pro-Ser-Lys-Asp-Leu-Ile-Ala-Glu-Ile-Gln-Lys-Gln-Gly-Gln-Gly-Gln

Another polynucleotide sequence of the invention, Polynucleotide Sequence II,
 35 also designated *pol7*, has the following sequence:

(II) *pol7*

TAC AGT GCA GGG GAA AGA ATA GTA GAC ATA ATA GCA ACA GAC
 ATA CAA ACT AAA GAA TTA CAA AAA CAA ATT ACA AAA ATT CAA
 AAT TTT CGG GTT TAT TAC AGG GAC AGC AGA GAT CCA CTT TGG
 5 AAA GGA CCA GCA AAG CTC CTC TGG AAA GGT GAA GGG GCA GTA
 GTA ATA CAA GAT AAT AGT GAC ATA AAA GTA GTG CCA AGA AGA
 AAA GCA AAG ATC ATT AGG GAT TAT GGA AAA CAG ATG GCA GGT
 GAT GAT

10 This sequence encodes the following amino acid sequence. (The italicized amino acids represent polypeptide BRU124F3X also disclosed herein.)

(XIII) *pol7*-aa Polypeptide Encoded by Polynucleotide Sequence (II) *pol7*

Tyr-Ser-Ala-Gly-Glu-Arg-Ile-Val-Asp-Ile-Ile-Ala-Thr-Asp-Ile-Gln-Thr-Lys-Glu-Leu-Gln-
 Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-
 15 Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-
 Ser-Asp-Ile-Lys-Val-Val-Pro-Arg-Arg-Lys-Ala-Lys-Ile-Ile-Arg-Asp-Tyr-Gly-Lys-Gln-
 Met-Ala-Gly-Asp-Asp

The subject polypeptides may be employed linked to a soluble macromolecular
 20 (e.g., not less than 5kDal) carrier. Conveniently, the carrier may be a poly(amino acid),
 either naturally occurring or synthetic, to which antibodies are unlikely to be encountered
 in human serum. Illustrative polypeptides include poly-L-lysine, bovine serum albumin,
 keyhole limpet hemocyanin, bovine gamma globulin, etc. The choice is primarily one of
 convenience and availability.

25 With such conjugates, there will be at least one molecule of at least one subject
 polypeptide per macromolecule and not more than about 1 per 0.5 kDal, usually not more
 than about 1 per 2 kDal of the macromolecule. One or more different polypeptides may be
 linked to the same macromolecule.

The manner of linking is conventional, employing such reagents as p-
 30 maleimidobenzoic acid, p-methyldithiobenzoic acid, maleic acid anhydride, succinic acid

anhydride, glutaraldehyde, etc. The linkage may occur at the N-terminus, C-terminus or at a site intermediate to the ends of the molecule. The subject polypeptide may be derivatized by linking, may be linked while bound to a support, or the like.

The polypeptides of the invention may be used as reagents in assays to detect
5 antibodies to HIV-1 or HIV-2 or antigens thereof. The polypeptides may be employed as labeled or unlabeled reagents depending upon their use (By label is intended a molecule which provides, directly or indirectly a detectable signal). Various labels may be employed, such as radionuclides, enzymes, fluorescers, chemilumescers, enzyme substrates, cofactors or inhibitors, particles, e.g., magnetic particles, combinations of
10 ligands and receptors, e.g., biotin and avidin, or the like. In addition the polypeptides may be modified in a variety of ways for binding to a surface, e.g., microwell plate, glass beads, chromatographic surface, e.g., paper, cellulose, silica gel, or the like. The particular manner by which the polypeptides are joined to another compound or surface is conventional and finds ample illustration in the literature. See, for example, U.S. Pat. Nos.
15 4,371,515; 4,487,715; and patents cited therein.

Various assay protocols may be employed for detecting the presence of either antibodies to retroviral proteins or retroviral proteins themselves. Of particular interest is using the polypeptide as the labeled reagent, where the label allows for a detectable signal, or binding the polypeptide, either directly or indirectly to a surface, where antibody or the
20 polypeptide in the sample will become bound to the polypeptide on the surface. The presence of human antibody bound to the polypeptide can then be detected by employing a xenogeneic antibody specific for human immunoglobulin, normally both human IgM and

IgG, or a labeled protein specific for immune complexes, e.g., RF factor or *S. aureus* Protein A.

Various heterogeneous protocols may be employed, either competitive or non-competitive. Polypeptide may be bound to a surface or support ("support") and labeled
5 antibody allowed to compete with antibody in the sample for the limited amount of bound polypeptide. The amount of label bound to the support would be related to the amount of competitive antibody in the sample.

Xenogeneic anti-human antibody, e.g., antibodies to the Fc region of IgG and IgM (immunoglobulins), could be bound to a support. The sample would be contacted with the
10 immunoglobulins and labeled polypeptide, whereby the amount of labeled polypeptide bound to the support would be indicative of the presence of the cognate antibodies.

Alternatively, homogeneous assays can be employed where the polypeptide is bound to an enzyme, fluorescer, or other label, where the binding of antibody to the polypeptide results in being able to discriminate between the label involved with a specific
15 binding pair complex and label which is not involved in the complex. For assays involving such techniques, see for example U.S. Patent Nos. 3,817,837; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876, whose disclosures are incorporated herein by reference.

As an illustration of the subject invention, the subject polypeptide may be
20 conjugated to a fluorescent molecule, such as fluorescein, rhodamine or umbelliferone. In this assay the fluorescence polarization is different between complexed and uncomplexed polypeptide conjugate. Apparatuses are available for measuring changes in fluorescence polarization, e.g., TDx supplied by Abbott Laboratories, Chicago, Illinois.

Illustrative of an assay technique is the use of a sample container, e.g. microwell plate wells, where the subject polypeptide or conjugates thereof are adhered to the container bottom and/or walls either covalently or noncovalently. The sample, normally human blood or serum diluted in appropriately buffered medium, is added to the container and a sufficient time allowed for complex formation between the polypeptide(s) and any cognate antibodies in the sample. The supernatant is removed and the container washed to remove nonspecifically bound proteins.

A labeled specific binding protein which specifically binds to the complex is employed for detection. To the container may be added xenogeneic antisera to human immunoglobulin, particularly anti-(human IgM and IgG) in an appropriately buffered medium. The xenogeneic antisera will normally be labeled with a detectable label, e.g., horseradish peroxidase. The label may then be detected. For example, with an enzyme, after removal of non-specifically bound enzyme label, a developer solution is added. The developer solution will contain an enzyme substrate and possibly enzyme cofactors, chromogens, etc., which, upon reaction, provide a colored, fluorescent, or chemiluminescent product which may be detected colorimetrically, fluorimetrically, or by photon counting, respectively.

The polypeptide can be prepared in a wide variety of ways. The polypeptide, because of its relatively short length, may be synthesized in solution or on a solid support in accordance with known protocols. See, for example, Stewart and Young, Solid Phase polypeptide Synthesis, 2nd ed., Pierce Chemical Co., 1984; and Tam et al, J. Am. Chem. Soc. (1983) 105:6442.

Alternatively, as discussed herein, recombinant DNA technology may be employed where a recombinant polynucleotide sequence may be prepared by employing single strands which code for the polypeptide or substantially complementary strands thereof. (See, for example, Maniatis, *supra*.)

5 Depending upon the nature of the assay, the physiological sample, e.g., saliva, blood, plasma, or serum, may be pretreated by dilution into an assay medium, which will usually be an aqueous buffered medium employing one of a variety of buffers, such as phosphate, tris, or the like. A preferred diluent is 5% w/v nonfat dry milk, .01% Proclin 300, .005% Antifoam A in 150mM sodium citrate. Usually the pH will be in the range of
10 about 6 to 9. The sample will then be combined with the reagent in accordance with appropriate protocol and sufficient time allowed for binding. Where a heterogeneous system is used, usually the binding stages will be followed by washes to minimize non-specific binding. At the end of the procedure, the label will be detected in accordance with conventional methods.

15 Besides the use of the subject polypeptide and its analogs in assays, the subject polypeptide may also find use by itself or in combination in vaccines. The polypeptides may be formulated in a convenient manner, generally at concentrations in the range of 1 ug to 20 mg/kg of host. Physiologically acceptable media may be used as carriers, such as sterile water, saline, phosphate buffered saline, and the like. Adjuvants may be employed,
20 such as aluminum hydroxide gel, or the like. Administration may be by injection, e.g., intramuscularly, intraperitoneally, subcutaneously, intravenously, etc. Administration may be one or a plurality of times, usually at one to four week intervals.

The immunoreactivity of the above-mentioned polypeptides I-IV, which immunologically mimic HIV-1 antigens, to eight known HIV-1 positive sera (i.e., GS91-[034, 037, 042, 046, 049, 052, 056, and 067], 11230, 11424, 11527, 11532 and 11535; all Western-blot all band positives) was examined, and the results are shown in Table 1A of Example 2. All of the polypeptides listed above were highly reactive to those samples.

Analogously, the immunoreactivity of each of the above-mentioned polypeptides, which immunologically mimic HIV-2 antigens, to five known HIV-2 positive sera (i.e., 92099, 92100, P-83, P-84, and P-86; Western-blot all band positive) was examined, and the results are shown in Table 1B of Example 2. The glycoprotein (gp) polypeptide, 41-2-3GC (a nonglycosylated polypeptide that is the subject of co-pending U.S. application No. 08/268,388) was highly reactive to all five samples. All of the polypeptides listed above were reactive to at least two of those five samples. The most reactive polypeptides were ROD 124C2X and ROD 124C5X; they were reactive to all five samples.

Example 1 - Synthesis of HIV Pol Polypeptides.

Series of HIV pol polypeptides were each synthesized by the sequential coupling of t-butyloxycarbonyl-protected amino acids onto 0.35 mmol p-methylbenzhydrylamine resin (Applied Biosystems Inc., Foster City, CA). Amino acid side chain protection was done by standard benzyl based groups. The tryptophan residue was protected by the formyl moiety. Completed polypeptides were deprotected and cleaved from the resin by the standard high HF procedure or the low-high HF procedure of Tam et al (J. Amer. Chem. Soc. 105:6442, 1983). The cleaved polypeptide was extracted from the resin in 50% acetic acid and subjected to Sephadex G-25 chromatography, using 20% acetic acid as a eluting solvent. Fractions containing polypeptide were pooled and lyophilized.

Example 2 - Immunoreactivity of Pol Polypeptides:

Polypeptides of the invention were tested for immunological reactivity by ELISA as previously described in U.S. Patent No. 4,629,783. Briefly, stock solutions of polypeptides of the invention at 0.5mg/ml were prepared in 2M urea/5% acetic acid.

- 5 Twelve milliliters of 1.2% acetic acid was placed in a 15 milliliter polypropylene tube and 48 microliters of the polypeptide stock solution added to the tube and mixed (the "coating solution"). Wells of microwell plates were filled with 100ul of the coating solution of the polypeptides and 100ul/well of 0.24M carbonate/0.2N NaOH added to raise the coating solution to an alkaline pH. The plate was covered and allowed to stand overnight at room
- 10 temperature. The coating solution was removed by aspiration and 300ul/well of Plate Blocking solution (containing per liter; 25g non-fat dry milk, 14.7g sodium citrate dihydrate, 8.47g sodium chloride and 0.05ml Antifoam A, 1.0 ml Kathon GC/ICP) was added and incubated for 1 hr. at room temperature. Blocking solution was removed by aspiration, and the plates were used immediately or allowed to air-dry and stored for later
- 15 use. To carry out the immunoassay, plasma samples were diluted 20-fold in Specimen Diluent (containing per liter; 44.1g sodium citrate dihydrate, 1.2ml Tween 20, 50g non-fat dry milk, 0.05ml Antifoam A, 50ml goat serum, 58.6g 2-[N-morpholino]ethane sulfonic acid, 92.9g triethanolamine hydrochloride, 1ml Proclin 300) and 100ul was added to individual wells. Samples were incubated for 30 minutes at 37° C, then removed and the
- 20 wells were washed five times with 0.1M NaCl/0.05% Tween 20 (350ul/wash). One hundred microliters of goat antihuman Ig-horseradish peroxidase conjugate diluted in citrate buffer, pH 7.0, containing 1% normal goat serum was added to each well for 30 minutes at 37° C prior to washing five times as above. The ELISA assay was developed

by adding 100ul/well of substrate solution (80ug/ml tetramethylbenzidine, 0.0015% hydrogen peroxide in citrate/phosphate buffer, pH 6.0) for 30 minutes at room temperature. Reactions were stopped with the addition of 100ul of 1N H₂SO₄ per well, and the ratio of the optical density at 450 nm to 630 nm was determined by an automated ELISA reader. The cut-off value for a positive result was set at 0.200 Absorbance Units above the average absorbance obtained from at least three known negative samples.

The results in Table 1A shows the reactivity of the polypeptides of the invention with HIV-1 positive and negative samples wherein the HIV-1 positive samples are GS91- (034, 037, 042, 046, 049, 052, 056, 067), 11230, 11424, 11527, 11532 and 11535, and the negative samples are PS1059-PS1062, PS1068, PS1071, and D21-D25.

TABLE 1A

Absorbance (450nm/630nm)**

Sample*	BRU124E	BRU124F1X	BRU124F3X	BRU124EX***
GS91-034	0.606	1.000	0.945	n.d.
GS91-037	0.507	1.584	1.551	n.d.
GS91-042	1.860	1.899	1.888	n.d.
GS91-046	1.598	1.848	1.831	n.d.
GS91-049	1.034	1.955	1.991	n.d.
GS91-052	1.606	1.852	1.917	n.d.
GS91-056	1.848	1.966	1.957	n.d.
GS91-067	1.960	2.110	2.110	n.d.
PS1071	0.036	0.040	0.046	n.d.
PS1062	0.041	0.047	0.046	n.d.
PS1070	0.034	0.039	0.043	n.d.
PS1061	0.020	0.023	0.021	n.d.
PS1069	0.034	0.039	0.039	n.d.
PS1060	0.027	0.052	0.044	n.d.
PS1068	0.028	0.039	0.037	n.d.
PS1059	0.043	0.046	0.049	n.d.
11535	n.d.	n.d.	n.d.	1.652
11527	n.d.	n.d.	n.d.	2.595
11532	n.d.	n.d.	n.d.	2.912
11424	n.d.	n.d.	n.d.	2.676
11230	n.d.	n.d.	n.d.	0.759
D21	n.d.	n.d.	n.d.	0.096
D22	n.d.	n.d.	n.d.	0.045
D23	n.d.	n.d.	n.d.	0.053
D24	n.d.	n.d.	n.d.	0.044
D25	n.d.	n.d.	n.d.	0.034

* Samples were diluted 1/40, instead of 1/20, in order to be able to compare the absorbance between different polypeptides. The GS91- (034, 037, 042, 046, 049, 052, 056, 067), 11230, 11424, 11527, 11532, and 11535) are known HIV-1 positive samples; samples PS1059-PS1062, PS1068, PS1071, and D21-25 are known HIV-1 negative samples.

** Highlighted values are positive values based on the cut-off values established by 0.200 + average negative. Cut-Off = 0.238 (except BRU124EX) The Cut-Off value for BRU124EX = 0.254

***The testing for the reactivity of BRU124EX was done separately at different date, using different samples.
n.d. = not done (or tested)

The results in Table 1B show the reactivity of the polypeptides of the invention with HIV-2 positive and negative samples wherein the HIV-1 positive samples are 92099, 92100, P-83, P-84 and P-86 and the negative samples are NBD1, NBD2, NBD3, AND NBD4.

5

TABLE 1B

Sample	Absorbance (450nm/630nm)*							
	<u>41-2-3GC</u>	<u>E1</u>	<u>EX</u>	<u>C1X</u>	<u>C2X</u>	<u>C3X</u>	<u>C5X</u>	<u>2A1</u>
92099	>3.00	0.41	0.73	0.24	1.61	0.78	1.77	1.91
92100	>3.00	0.47	0.75	0.26	1.91	0.88	1.82	1.86
P-83	2.82	0.44	1.05	0.10	1.02	0.45	1.06	0.08
P-84	>3.00	0.47	1.04	0.27	0.75	0.40	0.73	0.18
P-86	>3.00	0.16	0.23	0.16	0.35	0.20	0.34	0.13
NBD1	0.07	0.06	0.06	0.05	0.05	0.05	0.05	0.09
NBD2	0.11	0.11	0.12	0.11	0.11	0.11	0.12	0.11
NBD3	0.04	0.03	0.05	0.03	0.03	0.05	0.03	0.03
NBD4	0.07	0.05	0.06	0.05	0.04	0.05	0.07	0.05

Highlighted values are positive values based on the cut-off values established by 0.200 + average Negative. Cut-Off = 0.256

10

Known positive samples are 92099, 92100, P-83, P-84 and P-86 and the known negative samples are NBD1, NBD2, NBD3, AND NBD4.

An improvement on the specificity of HIV-1 and HIV-2 antibody detection by the incorporation of pol polypeptides (BRU124F3X and ROD124C5X) is illustrated by the study results shown in Table 1C. In this study, the pol polypeptides were coated on the microwell plate individually or together with envelope specific polypeptides, as mentioned

15

in U.S. Patent No. 5,439,792, the teachings of which are hereby incorporated by reference.

For the plate coating with individual pol polypeptides, the polypeptide was coated at 1.0 ug/ml. For the plate coating of the mixture of HIV-1 and HIV-2 polypeptides, the polypeptides were mixed together at the following concentrations in the coating buffer:

- 5 1.23 ug/ml for HIV-1 envelope polypeptide (designated as MNGC), 0.64 ug/ml for HIV-2 envelope polypeptide (designated as 41-2-3GC), 0.25 ug/ml for BRU124F3X and 0.125 ug/ml for ROD124C5X. The polypeptide coating procedure was the same as described earlier in the "immunoreactivity" section. The samples tested are known HIV-1 (Western blot all-band positive) samples (i.e., SAL040, SAL041, SAL059, SAL063, SAL064),
- 10 known HIV-2 (Western blot all-band positive) samples (i.e., 52, GB92000128, GB92000152, GB92000154, GB92000158), HIV-1 indeterminate samples (i.e., B3113, B5813, B5885, B7045, C000127, C000214, C000455) and HIV-2 indeterminate samples (i.e., B3123, B5605, B5810, B5826, B5832, B5875, B6312). Also included are the control samples used in the Genetic Systems® HIV-1/HIV-2 Peptide EIA kit (available from
- 15 Sanofi Diagnostics Pasteur, Inc., Redmond, Washington), namely HIV-1 positive control (PC-1), HIV-2 positive control (PC-2) and negative control (NC). Both the known positive and the indeterminate samples were also tested on a commercially available viral lysate based test, the Genetic Systems® HIV-1/HIV-2 EIA (Sanofi Diagnostics Pasteur, Inc., Redmond, Washington).

TABLE 1C
COMPARISON OF HIV-1/2 WESTERN BLOT ALL BAND POSITIVE
AND INDETERMINATE SAMPLE REACTIVITIES IN ELISA WITH POL
ONLY COATED PLATES AND FOUR PEPTIDE COATED PLATES

Sample	4 Peptides*			HIV-1 pol(BRU124F3X) Only			HIV-2 pol (ROD124C5X) Only			HIV-1/2 Viral Lysate***	
	A450/A630	S/CO	Pos/Neg**	A450/A630	S/CO	Pos/Neg**	A450/A630	S/CO	Pos/Neg**	S/CO	Pos/Neg**
PC-1	1.610	4.8	P	1.503	3.0	P	0.441	0.8	N	N.A.	N.A.
PC-2	1.639	4.9	P	1.539	3.1	P	0.451	0.9	N	N.A.	N.A.
	1.259	3.8	P	0.307	0.6	N	0.438	0.8	N	N.A.	N.A.
	1.221	3.7	P	0.301	0.6	N	0.560	1.1	P	N.A.	N.A.
	0.093	0.3	N	0.254	0.5	N	0.279	0.5	N	N.A.	N.A.
Cut-off	0.091	0.3	N	0.265	0.5	N	0.302	0.6	N	N.A.	N.A.
	0.332	N.A.		0.500	N.A.		0.531	N.A.		N.A.	N.A.
HIV-1 WB Pos.											
SAL040	2.985	9.0	P	2.956	5.9	P	2.709	5.1	P	>8.0	P
SAL041	3.028	9.1	P	2.876	5.8	P	2.555	4.8	P	>8.0	P
SAL059	2.957	8.9	P	2.796	5.6	P	2.238	4.2	P	>8.0	P
SAL063	3.009	9.1	P	2.790	5.6	P	2.714	5.1	P	>8.0	P
SAL064	2.934	8.8	P	2.893	5.8	P	2.865	5.4	P	>8.0	P
HIV-2 WB Pos.											
52											
GB92000128	2.972	9.0	P	2.738	5.5	P	2.669	5.0	P	>8.0	P
GB92000152	2.939	8.9	P	2.698	5.4	P	2.872	5.4	P	>8.0	P
GB92000154	2.904	8.7	P	2.633	5.3	P	2.743	5.2	P	>8.0	P
GB92000158	3.011	9.1	P	2.677	5.4	P	2.857	5.4	P	>8.0	P
	3.061	9.2	P	2.723	5.5	P	2.930	5.5	P	>8.0	P

TABLE 1C (continued)
**COMPARISON OF HIV-1/2 WESTERN BLOT ALL BAND POSITIVE
 AND INDETERMINATE SAMPLE REACTIVITIES IN ELISA WITH POL
 ONLY COATED PLATES AND FOUR PEPTIDE COATED PLATES**

Sample	4 Peptides*				HIV-1 pol (Bru124F3X) Only				HIV-2 pol (ROD124C5X) Only				HIV 1/2 Viral Lysate***	
	A450/A630	S/CO	Pos/Neg**	A450/A630	S/CO	Pos/Neg**	A450/A630	S/CO	Pos/Neg**	A450/A630	S/CO	Pos/Neg**	S/CO	Pos/Neg**
HIV-1 Indeterminates														
B3113	0.094	0.3	N	0.346	0.7	N	0.253	0.5	N	0.253	0.5	N	3.2	FP
B5813	0.063	0.2	N	0.303	0.6	N	0.244	0.5	N	0.244	0.5	N	3.0	FP
B5885	0.063	0.2	N	0.152	0.3	N	0.154	0.3	N	0.154	0.3	N	3.1	FP
B7045	0.062	0.2	N	0.241	0.5	N	0.208	0.4	N	0.208	0.4	N	3.5	FP
C000127	0.050	0.2	N	0.172	0.3	N	0.177	0.3	N	0.177	0.3	N	3.1	FP
C000214	0.056	0.2	N	0.157	0.3	N	0.155	0.3	N	0.155	0.3	N	5.4	FP
C000455	0.065	0.2	N	0.136	0.3	N	0.179	0.3	N	0.179	0.3	N	5.4	FP
HIV-2 Indeterminates														
B3123	0.051	0.2	N	0.142	0.3	N	0.188	0.4	N	0.188	0.4	N	3.2	FP
B5805	0.074	0.2	N	0.203	0.4	N	0.276	0.5	N	0.276	0.5	N	3.8	FP
B5810	0.053	0.2	N	0.204	0.4	N	0.205	0.4	N	0.205	0.4	N	4.3	FP
B5826	0.049	0.1	N	0.145	0.3	N	0.177	0.3	N	0.177	0.3	N	3.0	FP
B5832	0.057	0.2	N	0.183	0.4	N	0.195	0.4	N	0.195	0.4	N	3.2	FP
B5875	0.056	0.2	N	0.254	0.5	N	0.286	0.5	N	0.286	0.5	N	3.8	FP
B6312	0.027	0.1	N	0.150	0.3	N	0.155	0.3	N	0.155	0.3	N	2.8	FP

* 4 peptides = MNGC (1.23ug/ml); 41-2-3GC (0.64ug/ml); BRU124F3X (0.25ug/ml); ROD124C5X (0.125ug/ml)
 HIV-1 pol (BRU124F3X) Only and HIV-2 pol (124C5X) Only = 1.0ug/ml each

HIV-1 and HIV-2 WB Pos. = All band Western blot Positive samples

HIV-1 and HIV-2 Indeterminates = Western blot Indeterminates

** In Pos./Neg. columns : P = Positive; N = Negative; FP = False Positive

*** Genetic Systems® HIV-1/2 EIA (FDA approved)

Table 1C shows that all of the known HIV-1 and HIV-2 positive samples showed positive results when using either a single pol polypeptide coated plate or the plate coated with all four polypeptides. All HIV-1 and HIV-2 indeterminate samples showed negative results when using either a single pol polypeptide coated plate or the plate coated with all
5 four polypeptides. The indeterminate samples showed highly positive results (false positive) when tested using the viral lysate-based HIV-1/HIV-2 EIA. These results very clearly show that the polypeptide based EIA incorporating the pol polypeptides of the invention is highly sensitive and specific in detecting HIV positive samples.

Example 3 - Cloning *pol23* and *pol7*:

10 Both *pol23* and *pol7* recombinants were initially cloned in the pGEX system (Pharmacia). The cloned inserts were then moved into other expression vectors that provide "purification handles" to simplify analysis of gene expression.

Recombinant: pGEX/*pol23*

A PCR product was generated using HIV-1 viral DNA isolated from HIV-1 LAI
15 strain viral lysate as a template, and the primer pair
5' AGCACCATGGGGATCCCAGGGATTAGATATCAGTACAATG 3' and
5' AGTCAGAATTCATTGGCCTTGCCCCTGCTT 3'. PCR reactions used *UITma* DNA polymerase (Perkin-Elmer) to minimize the possibility of mutation due to polymerase error. The PCR product was digested with the restriction enzymes *Bam*HI and *Eco*RI and
20 inserted into *Bam*HI, *Eco*RI-digested pGEX 5X-1 (Pharmacia). The ligation mix was transformed into *E. coli* DH11S and ampicillin-resistant colonies selected (see Maniatis, *supra*).

Insert-containing colonies were initially identified by colony-PCR. This was followed by growth, plasmid isolation¹, and restriction analysis to demonstrate that the candidate clones contained the predicted restriction sites (see Maniatis, *supra*). A plasmid map of the resulting clone is provided in Figure 1.

5 Recombinant: pGEX/pol7.0

As described above, a PCR product was generated using a HIV-1 viral DNA template, and the primer pair

5' AGCACCATGGGGATCCCCTACAGTGCAGGGGAAAGAATA 3' and

5' GACTAGTCGACTCAATCATCACCTGCCATCTG 3'. PCR reactions used *UITma*

10 DNA polymerase (Perkin-Elmer) to minimize the possibility of mutation due to polymerase error. The PCR product was digested with the restriction enzymes *Bam*HI and *Sa*II and inserted into *Bam*HI, *Sa*II I-digested pGEX 5X-1. The ligation mix was transformed into *E. coli* DH11S and ampicillin-resistant colonies selected.

Insert-containing colonies were initially identified by colony-PCR. This was
15 followed by growth, plasmid isolation, and restriction analysis to demonstrate that the candidate clones contained the predicted restriction sites. A plasmid map of the resulting clone is provided in Figure 2.

Subcloning of pGEX/pol23 and pGEX/pol7.0 into expression vectors pQE42 and pThioHisA

20 Insert DNA was prepared from pGEX/pol23 and pGEX/pol7.0 by digestion with the enzymes *Bam*HI and *Sa*II. The commercial expression vectors pThioHisA (Invitrogen)

¹ Plasmid DNA was prepared from recombinant bacterial cultures grown overnight at 37°C in L-broth plus

and pQE42 (QIAGEN) were each digested with the enzymes *Bgl*II² and *Sal*I. In separate ligation reactions, each insert was joined to each vector. (see Maniatis, *supra*) Again, ampicillin-resistant transformants were selected in the *E. coli* host strain DH11S. Identity of the clones was verified by colony-PCR and restriction analysis of purified plasmid DNA. The resulting recombinants were designated pQE/*pol*23, pQE/*pol*7.0, pThioHis/*pol*23, and pThioHis/*pol*7.0. (Plasmid maps of the resulting clones are provided in Figures 3 through 6 respectively).

Example 4 - Protein Expression of Example 3 Clones:

All three plasmid expression systems, pGEX, pThioHisA, and pQE42, employing the *tac* promoter are negatively regulated (shut off) by glucose, and positively regulated (turned on) by the lactose analog IPTG.

Twenty-five ml cultures of each of the recombinants pQE/*pol*23, pQE/*pol*7.0, pThioHis/*pol*23, and pThioHis/*pol*7.0 were grown in complete T-broth plus 100mg/ml ampicillin, 1.0% glucose at 37°C (with shaking) until the optical density at 600 nm was between 2 and 6. Cells were then pelleted and resuspended in fresh glucose-free medium that contained 1mM IPTG to induce expression of the recombinant fusion protein. After 2 additional hours of incubation, the induced cultures were harvested by centrifugation at 2000 rpm for 10 minutes. The resulting supernatant medium was discarded and the cell pellets frozen at -70°C.

Frozen pellets were thawed and resuspended in 2.0 ml of an aqueous medium of 20 mM sodium phosphate, pH 7.8 and 500 mM NaCl. The cells were lysed by two cycles of 100mg/ml ampicillin using the QIAwell 8 Plus Plasmid Kit (QIAGEN).

freezing in a dry ice/ethanol bath followed by thawing in warm water and 10 short bursts of sonication. The resulting lysate was then centrifuged in an Eppendorf microfuge at maximum speed until pelleted. The lysate supernatants and pellets were used for further purification.

5 pQE/pol23, pQE/pol7.0: Ni-NTA purification

For these recombinants, the lysate pellets were dissolved in an aqueous buffer comprising 20 mM sodium phosphate, pH 7.8 and 8M urea. This suspension was bound to Ni-NTA agarose (QIAGEN) that was pre-equilibrated in the same buffer. Unbound material was washed away using the same buffer. Bound protein was then eluted with an
10 aqueous buffer comprising 20 mM sodium phosphate, 6.4 M urea and 100 mM EDTA. The resulting purified fusion proteins were analyzed by SDS-PAGE.

The lysate supernatants were also purified, using methods found below, however higher levels of recombinant protein were found in the lysate pellets.

pThioHis/pol23, pThioHis/pol7.0: Ni-NTA purification

15 For these recombinants, lysate supernatants were bound to Ni-NTA that was pre-equilibrated in an aqueous buffer comprising 20 mM sodium phosphate, pH 7.8 and 500 mM NaCl. Unbound material was washed away with the same buffer, and then again with an aqueous wash buffer (20 mM sodium phosphate, pH 6.0, 500 mM NaCl).

Bound protein was eluted in four successive steps using increasing concentration of
20 imidazole in the wash buffer (50 mM, 200 mM, 350 mM, 500 mM). SDS-PAGE analysis showed that 350 mM imidazole was the optimal elution condition for these recombinants.

² Note that the enzymes *Bam*HI and *Bgl*II produce cohesive ends that can be joined by ligation.

SDS-PAGE and Western Blot Analysis

Using standard laboratory procedures, samples of the resulting partially purified fusion proteins were separated by SDS-Page. Novex 4-20% polyacrylamide gradient gels were used.

- 5 In all cases it was observed that the recombinant fusion proteins migrated close to the predicted sizes as found in Table 2.

TABLE 2

Recombinant	Predicted fusion protein molecular weight	Purified from
pQE/pol23	46 kD	lysate pellet
pQE/pol7.0	33.5 kD	lysate pellet
pThioHis/pol23	37 kD	lysate supernatant
pThioHis/pol7.0	24 kD	lysate supernatant

- The separated proteins were also transferred to a nitrocellulose support for Western blot analysis. The semi-dry electrophoretic transfer method (Harlow and Lane, 10 Antibodies, a laboratory manual pp. 488-489) was used to transfer electrophoresed proteins to nitrocellulose membranes.

- After transfer, membranes were blocked with Blotto (50 mM Tris pH7.5, 150 mM NaCl, 5.0% nonfat dry milk, 0.1 % Tween-20) either overnight at 4°C or one hour at room temperature. After removing the blocking agent, the membrane was incubated with the 15 primary antibody³ diluted in Blotto, for one hour at room temperature. The primary antibody solution is then discarded and the blot is washed four times for 5 minutes each

³ Two mouse monoclonal antibodies against HIV *pol* were used at 1:4000 dilutions. A human serum positive to HIV was used at a 1:500 dilution.

with Blotto. The secondary antibody-enzyme conjugate⁴ is then added for a 30 minute room temperature incubation. After 30 minutes, the secondary antibody is discarded and the blot is again washed four times as earlier. This is followed by a rinse with water and then addition of the color substrate solution⁵.

5 Color development was stopped by washing with water after bands appeared. The pQE/pol23 and pThioHis/pol23 protein bands both reacted in Western blots using one of the mouse monoclonal antibodies, while the pQE/pol7.0 and pThioHis/pol7.0 protein bands both reacted with the other. All four bands were detected with the human HIV-1 positive serum.

10 **Example 5** - Enzyme Immunoassay (EIA) Testing:

EIA plates were coated with the partially purified recombinant fusion proteins. Each sample was coated at a dilution of 1:500 in 15 mM carbonate/35 mM bicarbonate coating buffer pH 9.6 overnight at room temperature. The coated plates were then "ON/OFF" blocked (2.5% non-fat dry milk), "ON/OFF" coated with a 4% sucrose-
15 solution, and air-dried overnight. As prepared, the plates may be stored in a sealed pouch with desiccant.

Each recombinant fusion protein was tested for reactivity with 16 HIV-1 positive samples, 8 normal donor samples, and 4 *E. coli*-reactive samples. The *E. coli*-reactive samples are samples that have previously been shown to have high reactivity to proteins

⁴ The secondary antibody conjugate was either horseradish peroxidase-conjugated goat-antimouse antibody (1:2000) in Blotto if the primary antibody was mouse monoclonal or alkaline phosphatase-conjugated goat-antihuman antibody (1:2000) in Blotto if the primary antibody was human serum.

⁵ Tetramethylbenzidine (TMB) (Vector Labs) was the substrate used with the horseradish peroxidase secondary antibody conjugate, while BCIP/NBT One-Component Substrate (Kirkegaard & Perry Laboratories Inc.) was used with the alkaline phosphatase secondary antibody conjugate.

from *E. coli* lysate. These were included to ensure that the reactivity we observe with HIV-1-positive samples is specific to the recombinant polypeptide and not directed toward contaminating *E. coli* proteins.

Briefly, the samples were diluted 1:101 in a specimen diluent (containing per liter;
5 44.1g sodium citrate dihydrate, 1.2ml Tween 20, 50g non-fat dry milk, 0.05ml Antifoam
A, 50ml goat serum, 58.6g 2-[N-morpholino]ethane sulfonic acid, 92.9g triethanolamine
hydrochloride, 1ml Proclin 300) and 200 μ l of the resulting mixtures were added to each
well of the previously prepared plates. The plates were covered and incubated at $37 \pm 1^\circ \text{C}$
for 60 minutes. The fluid was aspirated from each well and the plate was washed a
10 minimum of 5 times with a wash solution (0.1M NaCl/0.05% Tween 20).

100 μ l of a conjugate solution (goat antihuman Ig-horseradish peroxidase
conjugate diluted in citrate buffer, pH 7.0, containing 1% normal goat serum) was added to
each well. The plates were then covered and incubated for 60 minutes at $37 \pm 1^\circ \text{C}$.
Following incubation, the fluid was aspirated from each well and the plate was washed a
15 minimum of 5 times with the wash solution.

100 μ l of a chromogen solution (80ug/ml tetramethylbenzidine, 0.0015% hydrogen
peroxide in citrate/phosphate buffer, pH 6.0) was added to each well. The plates were then
covered and incubated in the dark for 30 minutes at room temperature. After removing the
cover and adding 100 μ l of a stopping reagent (1N H_2SO_4) the plates were read at an
20 absorbance of 450 nm with 615 nm to 630 nm as a reference. The ratio of the optical
densities at 450 nm to 630 nm was calculated. The cut-off value for a positive result was

set at 0.200 Absorbance Unites above the average absorbance obtained from at least three known negative samples. The results of these procedures are presented in Table 3.

TABLE 3

Samples	Coated Plates			
	pQE/pol23	pQE/pol7.0	pTH/pol23	pTH/pol7.0
B7095	2.122	1.903	0.557	1.68
C000218	1.553	2.11	0.046	2.042
C000582	1.557	1.618	0.208	1.219
B3137	2.075	2.155	0.949	1.933
B5878	2.142	0.107	0.732	0.064
B5879	2.255	2.13	1.075	2.14
B5847	0.042	0.132	0.01	0.049
C000024	0.051	2.278	0.018	2.225
B5853	1.671	2.212	0.509	2.154
B3138	0.916	1.732	0.2	1.295
B5895	0.944	0.717	0.027	0.587
C000130	0.438	0.598	0.021	0.299
C000136	0.947	1.622	0.08	1.385
B5889	1.438	1.139	0.25	0.649
B5822	0.331	0.05	0.051	0.031
SAL054	2.044	1.802	0.955	1.771
PSBC1171	0.07	0.021	0.019	0.014
PSBC1265	0.033	0.019	0.014	0.018
PSBC1341	0.014	0.01	0.009	0.01
PSBC1398	0.028	0.015	0.013	0.013
PSBC1481	0.027	0.017	0.014	0.016
PSBC1521	0.021	0.023	0.013	0.014
PSBC1657	0.028	0.017	0.014	0.011
PSBC1566	0.017	0.012	0.011	0.01
EC+1	0.039	0.028	0.015	0.025
EC+2	0.046	0.074	0.021	0.03
EC+3	0.048	0.024	0.014	0.03
EC+4	0.022	0.015	0.011	0.023

It is evident from the foregoing results that by employing one or a combination of polypeptides of the subject invention, a sensitive, accurate test for the presence of antibodies to HIV is provided. The subject polypeptides can be used by themselves or in combination with a screening assay or confirmatory assay, whereas the complete lysate or complete antigens may be employed as an independent procedure. The subject polypeptides can also be combined with polypeptides or proteins derived from the envelope or gag regions of HIV-1 or HIV-2 in a screening assay or confirmatory assay. Furthermore, because of the specificities of the polypeptides, one could anticipate that the DNA sequences coding for the polypeptides would also find similar specificity in a DNA hybridization assay.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

What is claimed is:

1. A method for determining the presence of antibodies to HIV in a body fluid, comprising:

- (a) contacting under conditions which permit immunospecific binding to form
5 a reaction mixture the body fluid with a composition containing at least one polypeptide or protein comprising the following amino acid sequences where oligopeptides having at least six amino acids which come within the sequence of at least one of the following polypeptide sequences will include epitopes within such sequence:

10

(I) BRU124E

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

15

(II) BRU124EX

W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-
Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-
20 Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Y-Z

20

(III) BRU124F1X

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
25 Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

25

(IV) BRU124F3X

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
30 Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Y-Z

30

(V) ROD 124E1

5

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-
Z

(VI) ROD 124EX

10

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-
Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-
Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-
Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

15

(VII) ROD 124C2X

20

W-X-Lys-Leu-Lys-Asp-Phe-Arg-
Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(VIII) ROD 124C1X

25

W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(IX) ROD 123C3X

30

X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

35

(X) POL2A1

W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-

Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-
Ala-Lys-Ile-Ile-Y-Z

5

(XI) ROD124C5X

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

10

(XII) *pol23-aa*

W-X-Pro-Gly-Ile-Arg-Tyr-Gln-Tyr-
Asn-Val-Leu-Pro-Gln-Gly-Trp-Lys-
Gly-Ser-Pro-Ala-Ile-Phe-Gln-Ser-Ser-
Met-Thr-Lys-Ile-Leu-Glu-Pro-Phe-Arg-
Lys-Gln-Asn-Pro-Asp-Ile-Val-Ile-Tyr-
Gln-Tyr-Met-Asp-Asp-Leu-Tyr-Val-
Gly-Ser-Asp-Leu-Glu-Ile-Gly-Gln-His-
Arg-Thr-Lys-Ile-Glu-Glu-Leu-Arg-Gln-
His-Leu-Leu-Arg-Trp-Gly-Leu-Thr-
Thr-Pro-Asp-Lys-Lys-His-Gln-Lys-
Glu-Pro-Pro-Phe-Leu-Trp-Met-Gly-
Tyr-Glu-Leu-His-Pro-Asp-Lys-Trp-Thr-
Val-Gln-Pro-Ile-Val-Leu-Pro-Glu-Lys-
Asp-Ser-Trp-Thr-Val-Asn-Asp-Ile-Gln-
Lys-Leu-Val-Gly-Lys-Leu-Asn-Trp-
Ala-Ser-Gln-Ile-Tyr-Pro-Gly-Ile-Lys-
Val-Arg-Gln-Leu-Cys-Lys-Leu-Leu-
Arg-Gly-Thr-Lys-Ala-Leu-Thr-Glu-
Val-Ile-Pro-Leu-Thr-Glu-Glu-Ala-Glu-
Leu-Glu-Leu-Ala-Glu-Asn-Arg-Glu-
Ile-Leu-Lys-Glu-Pro-Val-His-Gly-Val-
Tyr-Tyr-Asp-Pro-Ser-Lys-Asp-Leu-Ile-
Ala-Glu-Ile-Gln-Lys-Gln-Gly-Gln-Gly-
Gln-Y-Z

15

20

25

30

35

(XIII) *pol7-aa*

5 W-X-Tyr-Ser-Ala-Gly-Glu-Arg-Ile-
 Val-Asp-Ile-Ile-Ala-Thr-Asp-Ile-Gln-
 Thr-Lys-Glu-Leu-Gln-Lys-Gln-Ile-Thr-
 Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-
 Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-
 Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
 Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-
 10 Asp-Asn-Ser-Asp-Ile-Lys-Val-Val-Pro-
 Arg-Arg-Lys-Ala-Lys-Ile-Ile-Arg-Asp-
 Tyr-Gly-Lys-Gln-Met-Ala-Gly-Asp-
 Asp-Y-Z

15 wherein W is either a H of the amino terminal NH₂ group of the
 polypeptide or one or more additional amino acids bonded to the amino
 terminal NH₂ group of the polypeptide, the additional amino acids being
 selected to facilitate coupling of the polypeptide to a carrier protein or to a
 support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or
 more amino acids added to facilitate coupling; and Z is OH or NH;

- 20 (b) detecting whether immunospecific binding has occurred between the
 polypeptide and an antibody component of the body fluid in which an
 immune complex is formed and in which the detection of the immune
 complex indicates the presence of antibodies to HIV in the body fluid.
2. The method according to claim 1 in which the polypeptide is conjugated to

25 a carrier macromolecule.
 3. The method according to claim 1 in which the polypeptide is immobilized.
 4. The method according to claim 1 in which the immunospecific binding is
 detected by immunoprecipitation.

5. The method according to claim 1 in which the composition includes at least one polypeptide selected from a polymerase protein of HIV-1 and one selected from a polymerase protein of HIV-2.

6. The method according to claim 1 in which the polypeptide is modified by the substitution, addition or deletion of amino acid residues so that the modified polypeptide retains substantially all of the immunological reactivity of the unmodified polypeptide.

7. The method of claim 6 in which the immunological reactivity is measured by a method selected from the group consisting of radioimmunoprecipitation, immunofluorescence, and enzyme-linked immunosorbant assay.

8. The method according to claim 1 in which immunospecific binding between the polypeptide or protein and the antibody component of the body fluid is detected by:

- (i) removing unbound components from immune complexes formed in the immunoreaction mixture;
- (ii) adding a labeled antibody to the immunoreaction mixture, the labeled antibody being capable of immunospecifically binding to a component of the immune complexes and the label providing a detectable signal; and
- (iii) determining whether the labeled antibody binds to the immune complexes.

9. The method according to claim 8 in which the label comprises an enzyme which is detected by the addition of the enzyme substrate.

10. The method according to claim 8 in which the label comprises a radiolabel.

11. The method according to claim 8 in which the label comprises a fluorescent label.

12. A method for determining the presence of antibodies to HIV-1 in a body fluid, comprising:

- 5 (a) contacting under conditions which permit immunospecific binding to form a reaction mixture the body fluid with a composition containing at least one polypeptide or protein comprising the following amino acid sequences where oligopeptides having at least six amino acids which come within the sequence of the following polypeptide sequence will include epitopes
- 10 within such sequence:

(I) BRU124E

15 W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(II) BRU124EX

20 W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-
Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-
Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Y-Z

(III) BRU

25 W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

(IV) BRU124F3X

30 W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-

Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Y-Z

(XII) *pol23-aa*

5 W-X-Pro-Gly-Ile-Arg-Tyr-Gln-Tyr-
Asn-Val-Leu-Pro-Gln-Gly-Trp-Lys-
Gly-Ser-Pro-Ala-Ile-Phe-Gln-Ser-Ser-
Met-Thr-Lys-Ile-Leu-Glu-Pro-Phe-Arg-
10 Lys-Gln-Asn-Pro-Asp-Ile-Val Ile-Tyr-
Gln-Tyr-Met-Asp-Asp-Leu-Tyr-Val-
Gly-Ser-Asp-Leu-Glu-Ile-Gly-Gln-His-
Arg-Thr-Lys-Ile-Glu-Glu-Leu-Arg-Gln-
His-Leu-Leu-Arg-Trp-Gly-Leu-Thr-
15 Thr-Pro-Asp-Lys-Lys-His-Gln-Lys-
Glu-Pro-Pro-Phe-Leu-Trp-Met-Gly-
Tyr-Glu-Leu-His-Pro Asp-Lys-Trp-Thr-
Val-Gln-Pro-Ile-Val-Leu-Pro-Glu-Lys-
Asp-Ser-Trp-Thr-Val-Asn-Asp-Ile-Gln-
20 Lys-Leu-Val-Gly-Lys-Leu-Asn-Trp-
Ala-Ser-Gln-Ile-Tyr-Pro-Gly-Ile-Lys-
Val-Arg-Gln-Leu-Cys-Lys-Leu-Leu-
Arg-Gly-Thr-Lys-Ala-Leu-Thr-Glu-
Val-Ile-Pro-Leu-Thr-Glu-Glu-Ala-Glu-
25 Leu-Glu-Leu-Ala-Glu-Asn-Arg-Glu-
Ile-Leu-Lys-Glu-Pro-Val-His-Gly-Val-
Tyr-Tyr-Asp-Pro-Ser-Lys-Asp-Leu-Ile-
Ala-Glu-Ile-Gln-Lys-Gln-Gly-Gln-Gly-
Gln-Y-Z
30

(XIII) *pol7-aa*

35 W-X-Tyr-Ser-Ala-Gly-Glu-Arg-Ile-
Val-Asp-Ile-Ile-Ala-Thr-Asp-Ile-Gln-
Thr-Lys-Glu-Leu-Gln-Lys-Gln-Ile-Thr-
Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-
Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-
Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-
40 Asp-Asn-Ser-Asp-Ile-Lys-Val-Val-Pro-
Arg-Arg-Lys-Ala-Lys-Ile-Ile-Arg-Asp-

Tyr-Gly-Lys-Gln-Met-Ala-Gly-Asp-
Asp-Y-Z

- 5 wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂;
- 10 (b) determining whether immunospecific binding has occurred between the polypeptide and an antibody component of the body fluid in which the detection of immunospecific binding indicates the presence of antibodies to HIV in the body fluid.
13. A method for determining the presence of antibodies to HIV-2 in a body fluid, comprising:
- 15 (a) contacting under conditions which permit immunospecific binding to form a reaction mixture the body fluid with a composition containing at least one polypeptide or protein comprising the following amino acid sequences where oligopeptides having at least six amino acids which come within the sequence of at least one of the following polypeptide sequences will include epitopes within such sequence:
- 20

(V) ROD 124E1

25 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-
Z

(VI) ROD 124EX

5 W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-
Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-
Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-
Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(VII) ROD 124C2X

10 W-X-Lys-Leu-Lys-Asp-Phe-Arg-
Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
15 Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(VIII) ROD 124C1X

20 W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

25

(IX) ROD 123C3X

30 X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

35

(X) POL2A1

40 W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-
Ala-Lys-Ile-Ile-Y-Z

(XI) ROD124C5X

45 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-

Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂;

(b) detecting whether immunospecific binding has occurred between the polypeptide and an antibody component of the body fluid in which the detection of immunospecific binding indicates the presence of antibodies to HIV in the body fluid.

14. A polypeptide composition, immunoreactive to antibodies to HIV, comprising at least one of the following amino acid sequences:

(I) BRU124E

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(II) BRU124EX

W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-
Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-
Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Y-Z

(III) BRU124F1X

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-

Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

(IV) BRU124F3X

5

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-
Gln-Asp-Asn-Y-Z

10

(V) ROD 124E1

15

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-
Z

(VI) ROD 124EX

20

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-
Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-
Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-
Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

25

(VII) ROD 124C2X

30

W-X-Lys-Leu-Lys-Asp-Phe-Arg-
Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(VIII) ROD 124C1X

35

W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(IX) ROD 123C3X

5 X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

(X) POL2A1

10 W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-
Ala-Lys-Ile-Ile-Y-Z

(XI) ROD124C5X

15 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

(XII) *pol23-aa*

20 W-X-Pro-Gly-Ile-Arg-Tyr-Gln-Tyr-
Asn-Val-Leu-Pro-Gln-Gly-Trp-Lys-
Gly-Ser-Pro-Ala-Ile-Phe-Gln-Ser-Ser-
Met-Thr-Lys-Ile-Leu-Glu-Pro-Phe-Arg-
25 Lys-Gln-Asn-Pro-Asp-Ile-Val Ile-Tyr-
Gln-Tyr-Met-Asp-Asp-Leu-Tyr-Val-
Gly-Ser-Asp-Leu-Glu-Ile-Gly-Gln-His-
Arg-Thr-Lys-Ile-Glu-Glu-Leu-Arg-Gln-
His-Leu-Leu-Arg-Trp-Gly-Leu-Thr-
30 Thr-Pro-Asp-Lys-Lys-His-Gln-Lys-
Glu-Pro-Pro-Phe-Leu-Trp-Met-Gly-
Tyr-Glu-Leu-His-Pro Asp-Lys-Trp-Thr-
Val-Gln-Pro-Ile-Val-Leu-Pro-Glu-Lys-
Asp-Ser-Trp-Thr-Val-Asn-Asp-Ile-Gln-
35 Lys-Leu-Val-Gly-Lys-Leu-Asn-Trp-
Ala-Ser-Gln-Ile-Tyr-Pro-Gly-Ile-Lys-
Val-Arg-Gln-Leu-Cys-Lys-Leu-Leu-
Arg-Gly-Thr-Lys-Ala-Leu-Thr-Glu-
Val-Ile-Pro-Leu-Thr-Glu-Glu-Ala-Glu-

5 Leu-Glu-Leu-Ala-Glu-Asn-Arg-Glu-
Ile-Leu-Lys-Glu-Pro-Val-His-Gly-Val-
Tyr-Tyr-Asp-Pro-Ser-Lys-Asp-Leu-Ile-
Ala-Glu-Ile-Gln-Lys-Gln-Gly-Gln-Gly-
Gln-Y-Z

(XIII) *pol7-aa*

10 W-X-Tyr-Ser-Ala-Gly-Glu-Arg-Ile-
Val-Asp-Ile-Ile-Ala-Thr-Asp-Ile-Gln-
Thr-Lys-Glu-Leu-Gln-Lys-Gln-Ile-Thr-
Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-
Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-
15 Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-
Asp-Asn-Ser-Asp-Ile-Lys-Val-Val-Pro-
Arg-Arg-Lys-Ala-Lys-Ile-Ile-Arg-Asp-
Tyr-Gly-Lys-Gln-Met-Ala-Gly-Asp-
20 Asp-Y-Z

wherein W is either a H of the amino terminal NH₂ group of the polypeptide or one or more additional amino acids bonded to the amino terminal NH₂ group of the polypeptide, the additional amino acids being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent, Cys-Gly-Gly; or Lys-Lys, Y is absent, Cys or one or more amino acids added to facilitate coupling; and Z is OH or NH₂ and wherein amino acids in the sequence may be inserted, deleted and substituted so long as immunoreactivity to antibodies to HTV is retained.

15. The polypeptide composition of claim 14, wherein said polypeptide has formula (I) BRU124E

30 16. The polypeptide composition of claim 14, wherein said polypeptide has formula (II) BRU24EX.

17. The polypeptide composition of claim 14, wherein said polypeptide has formula (III) BRU124F1X.
18. The polypeptide composition of claim 14, wherein said polypeptide has formula (IV) BRU124F3X.
- 5 19. The polypeptide composition of claim 14, wherein said polypeptide has formula (V) ROD124E1.
20. The polypeptide composition of claim 14, wherein said polypeptide has formula (VI) ROD124EX.
21. The polypeptide composition of claim 14, wherein said polypeptide has
10 formula (VII) ROD124C2X.
22. The polypeptide composition of claim 14, wherein said polypeptide has formula (VIII) ROD124C1X.
23. The polypeptide composition of claim 14, wherein said polypeptide has formula (IX) ROD123C3X.
- 15 24. The polypeptide composition of claim 14, wherein said polypeptide has formula (X) POL2A1.
25. The polypeptide composition of claim 14, wherein said polypeptide has formula (XI) ROD124C5X.
26. The polypeptide composition of claim 14, wherein said polypeptide has
20 formula (XII) *pol*23-aa.
27. The polypeptide composition of claim 14, wherein said polypeptide has formula (XIII) *pol*7-aa.

28. A polypeptide composition, immunoreactive with HIV-1, comprising a polypeptide encoded by a polynucleotide sequence, wherein said polynucleotide sequence is:

5 CCA GGG ATT AGA TAT CAG TAC AAT
GTG CTT CCA CAG GGA TGG AAA GGA
TCA CCA GCA ATA TTC CAA AGT AGC
ATG ACA AAA ATC TTA GAG CCT TTT
AGA AAA CAA AAT CCA GAC ATA GTT
10 ATC TAT CAA TAC ATG GAT GAT TTG
TAT GTA GGA TCT GAC TTA GAA ATA
GGG CAG CAT AGA ACA AAA ATA GAG
GAG CTG AGA CAA CAT CTG TTG AGG
TGG GGA CTT ACC ACA CCA GAC AAA
15 AAA CAT CAG AAA GAA CCT CCA TTC
CTT TGG ATG GGT TAT GAA CTC CAT
CCT GAT AAA TGG ACA GTA CAG CCT
ATA GTG CTG CCA GAA AAA GAC AGC
TGG ACT GTC AAT GAC ATA CAG AAG
20 TTA GTG GGA AAA TTG AAT TGG GCA
AGT CAG ATT TAC CCA GGG ATT AAA
GTA AGG CAA TTA TGT AAA CTC CTT
AGA GGA ACC AAA GCA CTA ACA GAA
GTA ATA CCA CTA ACA GAA GAA GCA
25 GAG CTA GAA CTG GCA GAA AAC AGA
GAG ATT CTA AAA GAA CCA GTA CAT
GGA GTG TAT TAT GAC CCA TCA AAA
GAC TTA ATA GCA GAA ATA CAG AAG
CAG GGG CAA GGC CAA.

30 29. A polypeptide composition, immunoreactive with HIV-1, comprising a polypeptide encoded by a polynucleotide sequence, wherein said polynucleotide sequence is:

35 CCA GGG ATT AGA TAT CAG TAC AAT
GTG CTT CCA CAG GGA TGG AAA GGA
TCA CCA GCA ATA TTC CAA AGT AGC
ATG ACA AAA ATC TTA GAG CCT TTT
AGA AAA CAA AAT CCA GAC ATA GTT
ATC TAT CAA TAC ATG GAT GAT TTG
TAT GTA GGA TCT GAC TTA GAA ATA

5 GGG CAG CAT AGA ACA AAA ATA GAG
GAG CTG AGA CAA CAT CTG TTG AGG
TGG GGA CTT ACC ACA CCA GAC AAA
AAA CAT CAG AAA GAA CCT CCA TTC
CTT TGG ATG GGT TAT GAA CTC CAT
CCT GAT AAA TGG ACA GTA CAG CCT
ATA GTG CTG CCA GAA AAA GAC AGC
TGG ACT GTC AAT GAC ATA CAG AAG
10 TTA GTG GGA AAA TTG AAT TGG GCA
AGT CAG ATT TAC CCA GGG ATT AAA
GTA AGG CAA TTA TGT AAA CTC CTT
AGA GGA ACC AAA GCA CTA ACA GAA
GTA ATA CCA CTA ACA GAA GAA GCA
15 GAG CTA GAA CTG GCA GAA AAC AGA
GAG ATT CTA AAA GAA CCA GTA CAT
GGA GTG TAT TAT GAC CCA TCA AAA
GAC TTA ATA GCA GAA ATA CAG AAG
CAG GGG CAA GGC CAA.

20 30. A test kit for determining the presence of antibodies to HIV in a body fluid,
comprising an antigen and ancillary reagents suitable for use in detecting the presence of
antibodies to the antigen in said fluid; wherein said antigen is the polypeptide of claim 14.

31. The test kit of claim 30, wherein said antigen is the polypeptide of
claim 28.

25 32. The test kit of claim 30, wherein said antigen is the polypeptide of
claim 29.

33. A polynucleotide composition, comprising a polynucleotide sequence of:

30 CCA GGG ATT AGA TAT CAG TAC AAT
GTG CTT CCA CAG GGA TGG AAA GGA
TCA CCA GCA ATA TTC CAA AGT AGC
ATG ACA AAA ATC TTA GAG CCT TTT
AGA AAA CAA AAT CCA GAC ATA GTT
ATC TAT CAA TAC ATG GAT GAT TTG
TAT GTA GGA TCT GAC TTA GAA ATA
35 GGG CAG CAT AGA ACA AAA ATA GAG
GAG CTG AGA CAA CAT CTG TTG AGG

5 TGG GGA CTT ACC ACA CCA GAC AAA
AAA CAT CAG AAA GAA CCT CCA TTC
CTT TGG ATG GGT TAT GAA CTC CAT
CCT GAT AAA TGG ACA GTA CAG CCT
ATA GTG CTG CCA GAA AAA GAC AGC
TGG ACT GTC AAT GAC ATA CAG AAG
TTA GTG GGA AAA TTG AAT TGG GCA
AGT CAG ATT TAC CCA GGG ATT AAA
10 GTA AGG CAA TTA TGT AAA CTC CTT
AGA GGA ACC AAA GCA CTA ACA GAA
GTA ATA CCA CTA ACA GAA GAA GCA
GAG CTA GAA CTG GCA GAA AAC AGA
GAG ATT CTA AAA GAA CCA GTA CAT
15 GGA GTG TAT TAT GAC CCA TCA AAA
GAC TTA ATA GCA GAA ATA CAG AAG
CAG GGG CAA GGC CAA

wherein said polynucleotide sequence encodes a polypeptide which is immunoreactive with HIV-1.

20

34. A polynucleotide composition, comprising a polynucleotide sequence of:

25 CCA GGG ATT AGA TAT CAG TAC AAT
GTG CTT CCA CAG GGA TGG AAA GGA
TCA CCA GCA ATA TTC CAA AGT AGC
ATG ACA AAA ATC TTA GAG CCT TTT
AGA AAA CAA AAT CCA GAC ATA GTT
ATC TAT CAA TAC ATG GAT GAT TTG
TAT GTA GGA TCT GAC TTA GAA ATA
GGG CAG CAT AGA ACA AAA ATA GAG
30 GAG CTG AGA CAA CAT CTG TTG AGG
TGG GGA CTT ACC ACA CCA GAC AAA
AAA CAT CAG AAA GAA CCT CCA TTC
CTT TGG ATG GGT TAT GAA CTC CAT
CCT GAT AAA TGG ACA GTA CAG CCT
35 ATA GTG CTG CCA GAA AAA GAC AGC
TGG ACT GTC AAT GAC ATA CAG AAG
TTA GTG GGA AAA TTG AAT TGG GCA
AGT CAG ATT TAC CCA GGG ATT AAA
GTA AGG CAA TTA TGT AAA CTC CTT
40 AGA GGA ACC AAA GCA CTA ACA GAA
GTA ATA CCA CTA ACA GAA GAA GCA
GAG CTA GAA CTG GCA GAA AAC AGA
GAG ATT CTA AAA GAA CCA GTA CAT
GGA GTG TAT TAT GAC CCA TCA AAA

GAC TTA ATA GCA GAA ATA CAG AAG
CAG GGG CAA GGC CAA

5 wherein said polynucleotide sequence encodes a polypeptide which is immunoreactive
with HIV-1.




Figure 1




Figure 2




Figure 3






Figure 4

**Figure 5**

**Figure 6**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16160

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/70; C07K 7/00, 14/00, 14/16.

US CL : Please See Extra Sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 7.92, 7.93, 7.94, 7.95; 530/324, 325, 326, 327, 328, 329, 330, 350, 388.35.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, DIALOG. SEQUENCE SEARCH TO THE EXTENT POSSIBLE USING SEQUENCE LISTING FROM PRIORITY DOCUMENT.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	EP 267,802 A2 (GENETIC SYSTEMS CORPORATION) 18 May 1988, see entire document, particularly claim 14.	1-12, 14-15 ----- 13, 16-25, 30
Y	RATNER et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 24 January 1985. Vol. 313, pages 277-284, see Figure 1.	1-25, 30
Y	GUYADER et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 16 April 1987. Vol. 326, page 662-669, see Figure 2.	1-25, 30

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*A* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

26 OCTOBER 1998

Date of mailing of the international search report

18 JAN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT D. BUDENS

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16160

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,629,783 (COSAND) 16 December 1986, see entire document.	1-25, 30
Y	US 5,206,136 (MONJI et al.) 27 April 1993, see entire document.	1-25, 30
Y	US 5,439,792 (BLAKE et al.) 08 August 1995, see entire document.	1-25, 30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16160

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/5, 7.92, 7.93, 7.94, 7.95; 530/324, 325, 326, 327, 328, 329, 330, 350, 388.35.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-13, drawn to methods for detecting antibodies to HIV.

Group II, claim(s) 14-29, drawn to polypeptides of HIV.

Group III, claim(s) 30-32, drawn to test kits with antigens and ancillary reagents.

Group IV, claim(s) 33-34, drawn to polynucleotides encoding HIV proteins.

This application contains claims directed to more than one species of the generic invention. Those species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

Species of polypeptides I-XIII as listed in claims 1 and 14 as well as the species set forth in claims 28-29.

In addition, the invention of Group IV is directed to more than one species, namely the species of polynucleotides as set forth in claims 33-34. Should applicant elect to pay for additional group IV and desire for the species of claim 34 to be examined, then the appropriate additional search fees must be paid.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the peptides and proteins encompassed by the claimed invention are known in the art as evidenced by Ratner et al. *Nature* 313:277-284, 24 January 1985, and Guyader et al., *Nature* 326:662-669, 16 April 1987. Ratner et al. discloses the entire nucleotide and amino acid sequences of the proteins of HIV-1 (see Fig. 1). Likewise, Guyader et al. disclose the nucleotide and amino acid sequences of the proteins of HIV-2 (see Fig. 2). Thus the polypeptides and proteins encompassed by the claimed invention lack a special technical feature within the meaning of PCT Article 13.1 so as to form a single general inventive concept.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species each are directed to different proteins or nucleotide sequences which differ in their physical, chemical and immunological properties such as primary amino acid or nucleotide sequence and immunological reactivity with antibodies to HIV-1 or HIV-2 and are not so linked by a special technical feature within the meaning of PCT Article 13.1 so as to form a single general inventive concept.